Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
from TechCrunch https://ift.tt/z5Vo6nq
via IFTTT
from TechCrunch https://ift.tt/z5Vo6nq
via IFTTT
Comments
Post a Comment